Status:
COMPLETED
Gefitinib Usage and Outcomes in Routine Treatment
Lead Sponsor:
AstraZeneca
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to understand real world gefitinib usage patterns, patient characteristics and outcomes and to present these for a Caucasian population
Detailed Description
A multicentre, retrospective chart review study to characterise gefitinib usage and outcomes in routine treatment
Eligibility Criteria
Inclusion
- Patients who received gefitinib first line in the UK Single Payment Access (SPA) scheme
- Locally advanced or metastatic EGFR mutation positive NSCLC
- Supplied with first pack of gefitinib prior to 1st January 2012
Exclusion
- Patient was treated privately (i.e. outside the NHS)
- Gefitinib was second-line therapy following treatment failure on a prior therapy
Key Trial Info
Start Date :
June 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
157 Patients enrolled
Trial Details
Trial ID
NCT01818947
Start Date
June 1 2013
End Date
November 1 2013
Last Update
January 23 2014
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Elizabeth Hospital
Birmingham, United Kingdom
2
Velindre Nhs Trust
Cardiff, United Kingdom
3
Harrogate District Hospital
Harrogate, United Kingdom
4
Leeds Teaching Hospitals
Leeds, United Kingdom